<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We tested the effects of administration of a selective neuronal nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase (nNOS) inhibitor, ARL 17477, on ischemic cell damage and regional cerebral blood flow (rCBF), in rats subjected to transient (2 h) middle cerebral artery (<z:chebi fb="70" ids="34342">MCA</z:chebi>) occlusion and 166 h of reperfusion (n = 48) and in rats without <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion (n = 25), respectively </plain></SENT>
<SENT sid="1" pm="."><plain>Animals were administered ARL 17477 (i.v.): 10 mg/kg; 1 mg/kg; 3mg/kg; N-<z:chebi fb="13" ids="29785">nitro</z:chebi>-<z:chebi fb="0" ids="16467,29952">L-arginine</z:chebi> (L-NA) 10 mg/kg L-NA 1 mg/kg; and Vehicle </plain></SENT>
<SENT sid="2" pm="."><plain>Administration of ARL 17477 1 mg/kg, 3 mg/kg and 10 mg/kg reduced ischemic <z:mpath ids='MPATH_124'>infarct</z:mpath> volume by 53 (p &lt; 0.05), 23, and 6.5%, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>L-NA 1 mg/kg and 10 mg/kg increased <z:mpath ids='MPATH_124'>infarct</z:mpath> volume by 2 and 15%, respectively (p &gt; 0.05) </plain></SENT>
<SENT sid="4" pm="."><plain>Administration of ARL 17477 (10 mg/kg) significantly (p &lt; 0.05) decreased rCBF by 27 +/- 5.3 and 24 +/- 14.08% and cortical NOS activity by 86 +/- 14.9 and 91 +/- 8.9% at 10 min or 3 h, respectively, and did not alter mean arterial blood pressure (MABP) </plain></SENT>
<SENT sid="5" pm="."><plain>L-NA (10 mg/kg) significantly reduced rCBF by 23 +/- 9.8% and NOS activity by 81 +/- 7% and significantly (p &lt; 0.05) increased MABP </plain></SENT>
<SENT sid="6" pm="."><plain>Treatment with 3 mg/kg and 1 mg/kg ARL 17477 reduced rCBF by only 2.4 +/- 4.5 and 0%, respectively, even when NOS activity was reduced by 63 +/- 13.4 and 45 +/- 15.7% at 3 h, respectively, (p &lt; 0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>The data demonstrate that ARL 17477 inhibits nNOS in the rat brain and causes a dose-dependent reduction in <z:mpath ids='MPATH_124'>infarct</z:mpath> volume after transient <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion </plain></SENT>
</text></document>